Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions

Abstract

The spread of Enterobacteriaceae, primarily Klebsiella pneumoniae, producing KPC, VIM, IMP, and NDM carbapenemases, is causing an unprecedented public health crisis. Carbapenemase-producing enterobacteria (CPE) infect mainly hospitalized patients but also have been spreading in long-term care facilities. Given their multidrug resistance, therapeutic options are limited and, as discussed here, should be reevaluated and optimized. Based on susceptibility data, colistin and tigecycline are commonly used to treat CPE infections. Nevertheless, a review of the literature revealed high failure rates in cases of monotherapy with these drugs, whilst monotherapy with either a carbapenem or an aminoglycoside appeared to be more effective. Combination therapies not including carbapenems were comparable to aminoglycoside and carbapenem monotherapies. Higher success rates have been achieved with carbapenem-containing combinations. Pharmacodynamic simulations and experimental infections indicate that modification of the current patterns of carbapenem use against CPE warrants further attention. Epidemiological data, though fragmentary in many countries, indicate CPE foci and transmission routes, to some extent, whilst also underlining the lack of international collaborative systems that could react promptly and effectively. Fortunately, there are sound studies showing successful containment of CPE by bundles of measures, among which the most important are active surveillance cultures, separation of carriers, and assignment of dedicated nursing staff.

Figures

Fig 1

Schematic depiction of representative sequences from enterobacterial plasmids, showing the association of carbapenemase-encoding genes with various mobile elements. (I) The blaKPC-2-containing Tn4401 transposon from plasmid pNYC (GenBank accession no. EU176011) (180). (II and III) Representative VIM-encoding sequences from plasmids pNL194 (GenBank accession no. GU585907) (167) and pCC416 (GenBank accession no. AJ704863) (59), respectively. (IV) A blaIMP-carrying sequence from plasmid pFP10-2 (GenBank accession no. HQ651093) (146). (V and VI) Sequences containing blaNDM-1 carried by a plasmid from K. pneumoniae 05-506 (GenBank accession no. FN396876) (273) and by plasmid p271A (GenBank accession no. HQ162469) (218), respectively. (VII and VIII) The OXA-48-encoding transposon Tn1999 from plasmid pA-1 (GenBank accession no. AY236073) (217) and the blaOXA-163-containing segment from plasmid p6299 (GenBank accession no. HQ700343) (216), respectively.

Fig 2

Outcomes of infections caused by carbapenemase-producing Klebsiella pneumoniae, according to treatment regimen. Regimen A, combination therapy with ≥2 active drugs, one of which was a carbapenem; regimen B, combination therapy with ≥2 active drugs, not including a carbapenem; regimen C, monotherapy with an aminoglycoside; regimen D, monotherapy with a carbapenem; regimen E, monotherapy with tigecycline; regimen F, monotherapy with colistin; regimen G, inappropriate therapy. Regimen A was superior to regimens B, E, F, and G (for A versus B, E, F, and G, the P value was 0.02, 0.03, <0.0001, and <0.0001, respectively). Regimens B, C, and D were superior to regimen G (for B versus G, P = 0.014; for C versus G, P = 0.04; and for D versus G, P = 0.03).